Alvotech Seeks to End the AbbVie’s Wrong Monopoly on Humira and Develops New Biosimilar for Chronic Pain

 Alvotech Seeks to End the AbbVie’s Wrong Monopoly on Humira and Develops New Biosimilar for Chronic Pain

Shots:

  • Alvotech has filed a federal lawsuit to end the monopoly on AbbVie’s Humira for taking several improper steps to inflate its patent portfolio includes multiple patents on the same invention and obtain patents through inequitable conduct
  • Alvotech develops AVT02 as a biosimilar of Humira for chronic pain with equal in strength to Humira’s latest formulation and develops AVT02 as an interchangeable product and expects the results from its ongoing interchangeability study in Q2’21
  • The biosimilars are available across EU and in Japan, Canada, and Australia and expect to save US taxpayers and the overall healthcare system of $8-10B annually

Click here to­ read full press release/ article | Ref: BUSINESS WIRE | Image: BUSINESS WIRE

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post